Throughout the last three months, 4 analysts have evaluated Marinus Pharma (NASDAQ:MRNS), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.75, with a high estimate of $27.00 and a low estimate of $9.00. Observing a 141.67% increase, the current average has risen from the previous average price target of $9.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Marinus Pharma among financial experts...
ログインすると全部閲覧できます。
ログイン